



SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 2

Page 1 / 12

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Product Code(s) PZ03165
Trade Name: Not applicable
Chemical Family: Opioid analgesic

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as opioid analgesic

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Reproductive toxicity Category 1B
Effects on or via lactation Yes

OSHA Classification

Hazards not otherwise classified (HNOC)
Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200
Not applicable

2.2. Label elements



Signal word Danger

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 2 / 12
Version 2

Hazard statements

H360 - May damage fertility or the unborn child
H362 - May cause harm to breast-fed children

Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P263 - Avoid contact during pregnancy/while nursing
P308 + P313 - IF exposed or concerned: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
SODIUM CHLORIDE (CAS #: 7647-14-5)	<1	-	231-598-3	Not classified	Not classified	No data available	No data available
Butorphanol tartrate (CAS #: 58786-99-5)	< 0.2		261-443-5	Acute Tox. 4 (H302) Repr. 1B (H360D) Lact. (H362)	Not classified	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
---------------	----------	---------------------------	---------------------	--	------------------------------------	----------	----------------------

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 3 / 12
Version 2

				(EC) No. 1272/2008 [CLP]			
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Sodium citrate (CAS #: 68-04-2)	*	-	200-675-3	Not classified	Not classified	No data available	No data available
Citric acid monohydrate (CAS #: 5949-29-1)	*	-	Not Listed	Skin Irrit. 2 (H315) Eye Irrit. 2 (H319) STOT SE 3 (H335)	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Butorphanol tartrate 58786-99-5	570	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 4 / 12
Version 2

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing.

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 5 / 12
Version 2

When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical product used as. opioid analgesic.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Butorphanol tartrate

Pfizer OEL TWA-8 Hr: 3 µg/m³

SODIUM CHLORIDE

Latvia

Russia

TWA: 5 mg/m³;

MAC: 5 mg/m³

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section. General room ventilation is adequate unless the process generates dust, mist or fumes.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 6 / 12
Version 2

Hand protection	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Solution
Physical state	Liquid
Color	Clear, colorless
Odor	No information available.
Odor threshold	No information available

<u>Property</u>	<u>Values</u>
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 7 / 12
Version 2

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:

Toxicological properties of the formulation have not been investigated. The information in this section describes the potential hazards of the individual ingredients and the formulation.
Routes of exposure: eye contact , skin contact

Short term

May be harmful if swallowed. May cause eye irritation. May cause slight skin irritation.

Long Term:

Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system

Known Clinical Effects:

Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdose may also lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.

Acute toxicity

Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation

Based on available data, the classification criteria are not met.

Skin corrosion/irritation

Based on available data, the classification criteria are not met.

Respiratory or skin sensitization

Based on available data, the classification criteria are not met.

STOT - single exposure

Based on available data, the classification criteria are not met.

STOT - repeated exposure

Based on available data, the classification criteria are not met.

Reproductive toxicity

Based on available data, the classification criteria are not met.

Germ cell mutagenicity

Based on available data, the classification criteria are not met.

Carcinogenicity

Based on available data, the classification criteria are not met.

Aspiration hazard

Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 8 / 12
Version 2

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Butorphanol tartrate

Rat Oral LD50 570 mg/kg

Mouse Oral LD 50 395 mg/kg

Rat Intravenous LD 50 17 mg/kg

Mouse Intravenous LD 50 40.1 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Butorphanol tartrate	= 570 mg/kg (Rat)	-	-

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

Citric acid monohydrate

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Moderate

Irritation / Sensitization Comments:

Eye Irritation / Sensitization May cause eye irritation

Skin Irritation / Sensitization May cause mild skin irritation.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Butorphanol tartrate

4 Week(s) Monkey Oral 10 mg/kg/day NOAEL None identified

3 Month(s) Rat Subcutaneous 5 mg/kg/day NOAEL None identified

6 Month(s) Monkey Intramuscular 0.15 mg/kg/day LOAEL None identified

6 Month(s) Rat Intramuscular 0.4 mg/kg/day LOAEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Butorphanol tartrate

Reproductive & Fertility Rat Oral 2.5 mg/kg/day NOAEL Fertility

Embryo / Fetal Development Rat Oral Dose not specified NOAEL Not Teratogenic

Reproductive & Fertility Rat Subcutaneous 1 mg/kg/day LOAEL Fetal mortality

Fertility and Embryonic Development Rabbit Oral 30 mg/kg/day NOAEL Fertility

Fertility and Embryonic Development Rabbit Oral 60 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Butorphanol tartrate

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

Unscheduled DNA Synthesis Human fibroblast cells Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Butorphanol tartrate

2 Year(s) Rat Oral 60 mg/kg/day NOAEL Not carcinogenic

2 Year(s) Mouse Oral 60 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 9 / 12
Version 2

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Sodium citrate	Not PBT/vPvB PBT assessment does not apply
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Citric acid monohydrate	Not PBT/vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 10 / 12
Version 2

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Sodium citrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-675-3
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

Citric acid monohydrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

Butorphanol tartrate

CERCLA/SARA Section 313 de minimus %	Not Listed
--------------------------------------	------------

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 11 / 12
Version 2

**California Proposition 65
EINECS**

Not Listed
261-443-5

National regulations

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material

Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20

Not applicable

Major Accidents Ordinance SR 814.012

Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 16-Jun-2025

Page 12 / 12
Version 2

KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed H360D - May damage the unborn child H362 - May cause harm to breast-fed children

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 16-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.